Billionaire Joe Edelman’s 5 Stock Picks with Huge Upside Potential

2. Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Perceptive Advisors’ Stake: $67 Million

Analyst Upside Potential: 100%

Elite managers are piling into Nurix Therapeutics, Inc. (NASDAQ:NRIX) stock to capitalize on its leadership in Targeted Protein Degradation (TPD), a field many believe is the next frontier of medicine. A near-term catalyst for the shares has been the clinical momentum of its lead candidate, NX-5948. Recent data presentations have highlighted the drug’s ability to degrade Bruton’s tyrosine kinase (BTK) even in patients who have failed standard BTK inhibitors like ibrutinib. Analysts are specifically bullish on NX-5948’s unique ability to cross the blood-brain barrier. This allows it to target cancers that have spread to the central nervous system, a massive unmet need that existing drugs cannot effectively treat.

Nurix Therapeutics, Inc. (NASDAQ:NRIX) has an extensive collaboration network. The firm has multi-billion dollar partnerships with Gilead Sciences, Sanofi, and Pfizer. While retail sentiment is mixed due to current losses, $295 million trailing 12-month loss, the smart money is focused on the 44.4% annual revenue growth rate projected for the TPD market. Institutional investors are buying ahead of the initiation of Phase 3 trials for its lead assets. They view the current $1.7 billion valuation as a deep discount for a company with multiple best-in-class degraders in late-stage development.